HCPCS E0469 is officially defined as "Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device." HCPCS E0469 is referenced in 10 tracked payer policy changes from Connecticut Medicaid (HUSKY Health), Medicare/CMS - Transmittals, and 6 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS E0469 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Connecticut Medicaid is implementing new clinical review criteria for multiple medical services and devices effective August 1, 2025, including new policies for neuromuscular stimulation devices, orthognathic surgery, TMJ procedures, and several gene therapies. Several existing policies are being retired and will transition to InterQual criteria, while numerous other policies are being updated.
Section 110.8 of the Medicare Benefit Policy Manual is updated to reflect DMEPOS benefit category determinations for the 2025 biannual 1 and 2 Level II HCPCS coding cycles. Each listed code is assigned a benefit category, such as DME, Prosthetic Device, Back Brace, Leg Brace, Prosthetic (Artificial Leg or Arm), Lymphedema Compression Treatment Item, or No Medicare DMEPOS benefit category. This update makes no change in policy.
Humana Medicaid Virginia has clarified that Multi-Function Oscillation Lung Expansion (OLE) therapy devices, including BiWaze Clear System and Volara System (HCPCS E0469), are NOT covered for any indication due to insufficient clinical evidence. This is a non-coverage determination effective 07/22/2026. Billing teams must deny all claims for this service and educate providers that requests will be consistently denied under this plan.
Humana Medicare Advantage will NOT cover Multi-Function Oscillation Lung Expansion (OLE) therapy devices (HCPCS E0469) effective May 1, 2026. These respiratory therapy devices are considered not medically reasonable and necessary, meaning all claims will be denied.
Excellus BlueCross BlueShield policy 1.01.15, Airway Clearance Devices, has a current effective date of March 16, 2026. The November 20, 2025 annual review changed the conservative treatment requirement from an 'and' statement to an 'or' statement, separated the high frequency chest wall compression and intrapulmonary percussive ventilation (IPV) criteria into two policy statements, and added code E0469. High frequency chest wall compression and IPV devices are medically appropriate for members with a documented diagnosis that impairs clearance of secretions, a demonstrated need during exacerbations, and documented failure of, contraindication to, or lack of resources for standard treatments, while other uses such as COPD and continuous high-frequency oscillation are investigational.
Indiana Medicaid (IHCP) changed the rates for select durable medical equipment and medical supply HCPCS codes for dates of service on or after Jan. 1, 2026. For these items subject to the 21st Century Cures Act, the Medicaid allowed amount is the lowest non-zero 2026 Indiana Medicare DMEPOS Fee Schedule amount or competitive bidding single payment amount. Claims for the listed codes will be mass adjusted, as appropriate, and adjusted claims show on remittance advices beginning Aug. 12, 2026 with ICNs/Claim IDs that begin with 52.
Humana Medicaid in Virginia has established a new policy that does NOT cover Multi-Function Oscillation Lung Expansion (OLE) therapy devices, including both prescription devices like BiWaze Clear System and over-the-counter devices like Acapella. All claims for these services and devices will be denied.
Aetna considers chest physiotherapy by a respiratory therapist medically necessary at the initial home prescription, to stabilize the member and train family members or caregivers, and when the member's pulmonary condition is unstable. Aetna considers airway oscillating devices, mechanical percussors, PEP masks and postural drainage boards medically necessary for listed conditions such as cystic fibrosis, chronic bronchitis, bronchiectasis, immotile cilia syndrome, asthma and COPD. High-frequency chest compression systems and mechanical in-exsufflation devices are considered medically necessary only for the specific neuromuscular, bronchiectasis, cystic fibrosis, immotile cilia and lung transplant criteria in the policy, and the Intrapulmonary percussive ventilator, BiWaze Clear System, Volara OLE device, Simeox device and high-frequency chest compression for other indications are considered experimental, investigational or unproven.
High-frequency chest wall compression devices and intrapulmonary percussive ventilation devices may be considered medically necessary in individuals with cystic fibrosis or chronic diffuse bronchiectasis when standard chest physical therapy has failed or is unavailable or not tolerated. An oscillatory positive expiratory pressure device may be considered medically necessary in individuals with hypersecretory lung disease who have difficulty clearing secretions and recurrent disease exacerbations. Other applications, including use as an adjunct to chest physical therapy and use in chronic obstructive pulmonary disease or respiratory conditions associated with neuromuscular disorders, are considered investigational.
Effective January 3, 2025, Premera HMO medical necessity criteria for Dupixent (dupilumab) in moderate to severe asthma were updated, requiring two or more asthma exacerbations in the previous 12 months requiring oral corticosteroids, or one or more exacerbations requiring hospitalization, an emergency department visit, or an urgent care visit, or forced expiratory volume in 1 second of less than 80% predicted, with a blood eosinophil count greater than 300 cells/mcL. The same effective date added Humira (adalimumab) criteria for psoriatic arthritis, Crohn's disease, ulcerative colitis, uveitis, sarcoidosis and pyoderma gangrenosum, moved Inflectra (infliximab-dyyb) to a first-line TNF-alpha antagonist option for several indications, and removed Hyrimoz (adalimumab-adaz) from first-line options. A new Shoulder Arthroplasty policy (7.01.590) with medical necessity criteria for total, reverse, hemi, and revision shoulder arthroplasty is also listed under the January 3, 2025 effective date, and Restasis (cyclosporine ophthalmic emulsion) was added for dry eye disease in individuals aged 18 years and older effective October 1, 2024.
Watch E0469
Get one email when a payer policy names E0469, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for E0469
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for E0469 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.